Date: <u>Jan. 12th, 2022</u>	
Your Name: <u>Hajime Oi</u>	
Manuscript Title: KRAS G12V	utation as an acquired resistance mechanism after treatment with dabrafenib
trametinib in non-small cell l	g cancer harbouring the BRAF V600E mutation: a case report
Manuscrint number (if know	PCM-21-55

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	XNone		
	in other board, society,			
	committee or advocacy group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			
Plea	Please summarize the above conflict of interest in the following box:			
N	one.			

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>Jan 17, 2022</u>				
Your Name:	Kiyotaka Yoh			
Manuscript Title	KRAS G12V mutation as an acquired resistance mechanism after treatment with dabrafenib and			
trametinib in no	n-small cell lung cancer harbouring the BRAF V600E mutation: a case report			
Manuscript nun	ber (if known): PCM-21-55			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	AstraZeneca	My institution
	any entity (if not indicated	Lilly	My institution
	in item #1 above).	Pfizer	My institution
		Daiichi sankyo	My institution
		Abbvie	My institution
		Taiho	My institution
		MSD	My institution
		Takeda	My institution
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
	_		
5	Payment or honoraria for	AstraZeneca	honoraria
	lectures, presentations,	Bristol-Myers Squibb	honoraria
	speakers bureaus,	Chugai	honoraria
	manuscript writing or		
	educational events		
		Daiichi sankyo	honoraria
		Janssen	honoraria
		Eli Lilly	honoraria
		Taiho	honoraria
		Novartis	honoraria
		Kyowa kirin	honoraria
		Boehringer Ingelheim	honoraria
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

K.Y. reports research support from AstraZeneca, Eli Lilly, Pfizer, Daiichi sankyo, Abbvie, Taiho, Takeda and MSD, and personal fees (honoraria) from AstraZeneca, Bristol-Myers Squibb, Chugai, Daiichi sankyo, Janssen, Eli Lilly, Taiho, Novartis, Kyowa kirin and Boehringer Ingelheim.

Please place an "X" next to the following statement to indicate your agreement:

_ X __ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: <u>Jan 17, 2022</u>				
Your Name: Shingo Matsumo	oto			
Manuscript Title: KRAS G12V mu	tation as an acquired resistance mechanism after treatment with dabrafenib and			
trametinib in non-small cell lung	cancer harbouring the BRAF V600E mutation: a case report			
Manuscript number (if known): _	PCM-21-55			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Chugai Novartis Eli Lilly	My institution My institution My institution

		Merck	My institution
		MSD	My institution
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for	AstraZeneca	honoraria
	lectures, presentations,	Chugai	honoraria
	speakers bureaus,	Novartis	honoraria
	manuscript writing or		
	educational events		
		Pfizer	honoraria
_		Eli Lilly	honoraria
6	Payment for expert	XNone	
	testimony		
_			
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
42	Descript of any	V. N.	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13		X None	
13	Other financial or non- financial interests	^NOTIE	
	illianciai iliterests		

S.M. reports research support from Chugai, Novartis, Eli Lilly, Merck and MSD, and personal fees (honoraria) from AstraZeneca, Chugai, Novartis, Pfizer and Eli Lilly.

Please place an "X" next to the following statement to indicate your agreement:

_ X __ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: <u>Jan 17, 2022</u>				
Your Name: Hiroki Izumi		_		
Manuscript Title: KRAS G12V mu	<u>tation as an acquired resistance mechanism after treatment w</u>	ith dabrafenib and		
trametinib in non-small cell lung	cancer harbouring the BRAF V600E mutation: a case report			
Manuscript number (if known):	PCM-21-55			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past Amgen	36 months My institution
3	Royalties or licenses	XNone	

4	Consulting for	V. Nava	
4	Consulting fees	XNone	
5	Payment or honoraria for	Ono	honoraria
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
	•		
7	Support for attending	XNone	
-	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X None	
	materials, drugs, medical	<u></u>	
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests	XNONE	
	manda micrests		

H.I. reports research support from Amgen and personal fees (honoraria) from Ono.

Please place an "X" next to the following statement to indicate your agreement:

Date: Jan 17, 2022		
Your Name: Yuji Shibata		
Manuscript Title: KRAS G12V mutat	on as an acquired resistance mechanism after tr	eatment with dabrafenib and
trametinib in non-small cell lung car	cer harbouring the BRAF V600E mutation: a case	e report
Manuscrint number (if known):	PCM-21-55	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initialXNone	planning of the work
2	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	MSD XNone	36 months My institution
4	Consulting fees	XNone	

5	Payment or honoraria for	Ono	honoraria
	lectures, presentations,	Pfizer	honoraria
	speakers bureaus,	Chugai	honoraria
	manuscript writing or		
	educational events	Novartis	honoraria
		Eli Lilly	
		-	honoraria honoraria
		Bristol-Myers Squibb AstraZeneca	honoraria
		Taiho	
6	Daymant for ayport		honoraria
ь	Payment for expert testimony	XNone	
	testimony		
7	Support for attending	X None	
/	meetings and/or travel	xnone	
	lineetings and/or traver		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	V None	
11	Stock or stock options	XNone	
12	Receipt of equipment,	X None	
12	materials, drugs, medical	^NUITE	
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests		
	ariciai irrecrests		

Y.S. reports research support from MSD, and personal fees (honoraria) from Ono, Pfizer, Chugai, Novartis, Eli Lilly,
Bristol-Myers Squibb, AstraZeneca and Taiho.

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>Jan 17, 20</u>	2	
Your Name:	etsuya Sakai	_
Manuscript Title	KRAS G12V mutation as an acquired resistance mechanism after treatment with dabrafenib an	d
trametinib in no	small cell lung cancer harbouring the BRAF V600E mutation: a case report	_
Manuscript num	er (if known): PCM-21-55	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	XNone	
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	X None	30 months
_	any entity (if not indicated	XNone	
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events X_None				
testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Table Receipt of equipment, materials, drugs, medical writing, gifts or other Table Support for attending meetings and without and	5	lectures, presentations, speakers bureaus, manuscript writing or		
meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other	6	•	XNone	
pending Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None X_None X_None X_None X_None	7		XNone	
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other X None	8	-	XNone	
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other 13 Leadership or fiduciary role XNone	9	Safety Monitoring Board or	XNone	
12 Receipt of equipment, materials, drugs, medical writing, gifts or other	10	in other board, society, committee or advocacy	XNone	
materials, drugs, medical writing, gifts or other	11	Stock or stock options	XNone	
	12	materials, drugs, medical writing, gifts or other services	XNone	
13 Other financial or non-financial interests XNone	13		XNone	

T.S. reports personal fees (honoraria) from Chugai and AstraZeneca.	

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>Jan 17, 20</u>)22				
Your Name:	Kaname Nosaki				
Manuscript Title	e: KRAS G12V mutation as	an acquired resis	stance mechanish	n after treatment with	dabrafenib and
trametinib in no	on-small cell lung cancer h	arbouring the BR	AF V600E mutation	n: a case report	
Manuscript nun	nber (if known):	PCM-21-55			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
2	Grants or contracts from	Time frame: past Chugai	36 months My institution
	any entity (if not indicated in item #1 above).	Takeda	My institution
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5		Pfizer	honoraria

	Payment or honoraria for	Chugai	honoraria
	lectures, presentations, speakers bureaus, manuscript writing or educational events	Takeda	honoraria
		Novartis	honoraria
		AstraZeneca	honoraria
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
_			
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10		V. Name	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

K.N. reports research support from Chugai and Takeda, and personal fees (honoraria) from Pfizer, Chugai, Takeda,
Novartis and AstraZeneca.

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>Jan 17, 2022</u>	
Your Name: Yoshitaka Zenke	
Manuscript Title: <u>KRAS G12V mutat</u>	on as an acquired resistance mechanism after treatment with dabrafenib and
trametinib in non-small cell lung ca	cer harbouring the BRAF V600E mutation: a case report
Manuscript number (if known):	PCM-21-55

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	AstraZeneca MSD Daiichi-Sankyo	My institution My institution My institution
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5		Pfizer	honoraria

	Payment or honoraria for	Chugai	honoraria
	lectures, presentations,	Takeda	honoraria
	speakers bureaus,		
	manuscript writing or educational events		
	educational events	AstraZeneca	honoraria
		Bristol-Myers Squibb	honoraria
		Ono pharmaceutical	honoraria
		Boheringer-Ingelheim	honoraria
		Taiho	honoraria
		Novartis	honoraria
		MSD	honoraria
		Eli Lilly	honoraria
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	g ,		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
13	financial interests	^NOITE	
	initaliciai interests		

Y.Z. reports research support from AstraZeneca, MSD, Daiichi-Sankyo and personal fees (honoraria) from Pfizer, Chugai, Takeda, AstraZeneca, Bristol-Myers Squibb, Ono pharmaceutical, Boheringer-Ingelheim, Taiho, Novartis, MSD and Eli Lilly.

Please place an "X" next to the following statement to indicate your agreement:

_ X	$_$ I certify that I have answered every question and have not altered the wording of any of the questions on this
f	form.

Date: <u>Jan 17, 2022</u>				
Your Name: <u>Koich</u>	ni Goto			
Manuscript Title: <u>KRA</u>	S G12V mutation as an acquired re	sistance mechanism after treatment with dabrafenib and		
rametinib in non-small cell lung cancer harbouring the BRAF V600E mutation: a case report				
Manuscript number (i	if known): PCM-21-55			
-				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		
	Time frame: past 36 months			
2	Grants or contracts from	Boehringer Ingelheim	My institution	
	any entity (if not indicated	Bristol-Myers Squibb	My institution	
	in item #1 above).	Chugai	My institution	
		Daiichi sankyo	My institution	
		Eisai	My institution	

		Eli Lilly	My institution
		Guardant Health	My institution
		Janssen	My institution
		Kyowa Kirin	My institution
		Life Technologies Japan	My institution
		MSD	My institution
		Novartis	My institution
		Ono	My institution
		Otsuka	My institution
		Pfizer	My institution
		Taiho	My institution
		Takeda	My institution
3	Royalties or licenses	X None	,
	,		
4	Consulting fees	XNone	
5	Payment or honoraria for	Bristol-Myers Squibb	honoraria
	lectures, presentations,	Chugai	honoraria
	speakers bureaus,	Daiichi sankyo	honoraria
	manuscript writing or	·	
	educational events		
		Eisai	honoraria
		Eli Lilly	honoraria
		Haihe Biopharma	honoraria
		Ignyta	honoraria
		Janssen	honoraria
		KISSEI	honoraria
		Kyowa Kirin	honoraria
		LOXO Oncology	honoraria
		Medical & Biological	honoraria
		Laboratories	
		Merck Biopharma	honoraria
		Merus	honoraria
		MSD	honoraria
		Ono	honoraria
		Pfizer	honoraria
		Sumitomo Dainippon Pharma	honoraria
		Shanghai Haihe	honoraria
		Sysmex Corporation	honoraria
		Taiho	honoraria
		Takeda	honoraria
		Хсоо	honoraria
6	Payment for expert	XNone	
	testimony		
7		XNone	

	Support for attending meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

K.G. reports research support from Boehringer Ingelheim, Bristol-Myers Squibb, Chugai, Daiichi sankyo, Eisai, Eli Lilly, Guardant Health, Janssen, Kyowa Kirin, Life Technologies Japan, MSD, Novartis, Ono, Otsuka, Pfizer, Taiho and Takeda, and personal fees (honoraria) from Bristol-Myers Squibb, Chugai, Daiichi sankyo, Eisai, Eli Lilly, Haihe Biopharma, Ignyta, Janssen, KISSEI, Kyowa Kirin, LOXO Oncology, Medical & Biological Laboratories, Merck Biopharma, Merus, MSD, Ono, Pfizer, Sumitomo Dainippon Pharma, Shanghai Haihe, Sysmex Corporation, Taiho, Takeda, and Xcoo.

Please place an "X" next to the following statement to indicate your agreement: